Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.

Author: , Amustio DíezElena, BoqueConcepcion, CarrascosaGuiomar Bautista, Casado-MonteroLuis Felipe, ClaudianiSimone, De Las Heras RodríguezNatalia, Del Carmen García GarayMaría, FernándezMaria Ángeles, GarcíaAbelardo Bárez, García-GutiérrezValentín, GiraldoPilar, GonzálezGloria, GuineaJose María, Hernandez-BoludaJuan Carlos, HernánNuria, Jimenez-VelascoAntonio, LorenzoJose Luis López, Martin MateosMaría Luisa, Martinez-TrillosAlejandra, Martí-TutusausJosep Maria Martí, MilojkovicDragana, Ortega RivasFernando, OrtíGuillermo, PayerÁngel Ramírez, Piris-VillaespesaMiguel, PorteroAngeles, PuertaJose Manuel, PérezAna Iglesias, RamirezMaria Jose, RomeroEsperanza, RomoAndres, RosellAna, RuizBeatriz Cuevas, SaavedraSilvanna Saavedra, SebrangoAna, SenínAlicia, SteegmannJuan Luis, TallonJosé, ValenciaSandra, VallansotRolando Omar, VázquezIsabel Mata

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Bosutinib was effective in 62 CML patients who had failed prior treatment with imatinib, nilotinib, and dasatinib. The overall probabilities of achieving complete cytogenetic response (CCyR) and major molecular response (MMR) were 25% and 24%, respectively. Bosutinib was well tolerated but pleural effusions and diarrhea were common side effects.
Paper Details　
Original Abstract of the Article :
Bosutinib is a second-generation tyrosine kinase inhibitor (2GTKI) approved at 400 mg once daily (QD) as first-line therapy in patients with chronic myeloid leukemia (CML) patients and at 500 mg QD in patients who are resistant to or intolerant of prior therapy. In clinical practice, bosutinib is of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00277-018-3507-2

データ提供：米国国立医学図書館（NLM）

Bosutinib: A New Camel in the Desert of Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a formidable foe, like a relentless sandstorm in the desert. This research examines the effectiveness of bosutinib, a second-generation tyrosine kinase inhibitor (2GTKI), in treating CML patients who have failed other therapies. Think of bosutinib as a new camel in the caravan, ready to take on the difficult journey.

A Promising New Route

The study found that bosutinib could be a valuable treatment option for CML patients who have become resistant to previous therapies. The researchers observed that bosutinib achieved complete cytogenetic response (CCyR) and major molecular response (MMR) in a significant number of patients, indicating its potential to control the disease. It's like finding a new path through the desert, offering hope for a more favorable outcome.

Navigating the Terrain

However, the research also highlights the importance of considering prior treatment response and potential side effects. The study found that bosutinib was most effective in patients who had achieved CCyR before starting treatment. It's like having a camel that is already familiar with the terrain and can navigate the challenges more effectively. The research also emphasizes the need to monitor and manage potential side effects.

Dr.Camel's Conclusion

This research offers hope for CML patients who have exhausted other treatment options. Bosutinib could be a valuable weapon in the fight against CML, but it's important to understand its limitations and potential side effects. The journey through the desert of CML requires a thoughtful approach, using the right tools and being aware of the challenges that lie ahead.

Date :
  1. Date Completed 2019-01-28
  2. Date Revised 2019-01-28
Further Info :

Pubmed ID

30446802

DOI: Digital Object Identifier

10.1007/s00277-018-3507-2

Related Literature

Article Analysis
・Side Effects of bosutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.